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Introduction: Medulloblastoma, the most frequent brain tumor in childhood, also occurs with a wide range of
characteristics in adult patients. Late relapse is common in adult medulloblastoma, and the overall survival of
relapsed patients usually ranges from 12 to 15 months. Treatment at recurrence is still debated and after
reoperation includes stereotactic or normofractionated radiotherapy, and high-dose chemotherapy with autologous
bone marrow transplantation.
Case presentation: We report on the case of a 31-year-old Caucasian woman who underwent re-irradiation for
a recurrence of medulloblastoma at nine years after first irradiation (56Gy), focusing on the radiobiological
background and a review of previous studies involving re-irradiation of recurrent medulloblastoma. After surgical
excision of the relapsed tumor and medical multi-agent treatment, the site of recurrence was treated using
three-dimensional conformal radiotherapy to a total dose of 52.8Gy (1.2Gy/fraction/twice daily). A total biological
equivalent dose of 224.6Gy (α:β = 2 Gy) was delivered to the posterior fossa (first and second treatments). No
radionecrosis or local recurrence was evident at 18 months after re-irradiation.
Conclusion: Re-irradiation can be considered a possible and safe treatment in selected cases of recurrent
medulloblastoma in adults. The reported radiobiological considerations could be useful in other cases involving
re-irradiation of brain tumors.
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Medulloblastoma is a primitive neuro-ectodermal tumor
that is the most frequent primary brain neoplasm in
childhood. About 50% of these tumors occur in children
aged less than five years, whereas they are rare in adoles-
cents and young adults. Medulloblastoma behaves differ-
ently in adults than in children, and is identified as a
different biological and clinical entity [1]. It exhibits a
higher proportion of desmoplastic histological character-
istics than childhood medulloblastoma and shows a
higher incidence within the cerebellar hemispheres, thus
featuring different proliferative and apoptotic indices* Correspondence: buglione@med.unibs.it
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reproduction in any medium, provided the orand having a tendency for late relapse [2]. The applica-
tion of pediatric strategies in the management of this
tumor in adults has shown some success. As the data in
the literature are based on retrospective studies, treat-
ments have been neither randomized nor uniform. How-
ever, some treatment cornerstones have been identified.
The first step is surgical excision carried out as com-
pletely as possible without resulting in major neuro-
logical impairment. The second step is radiotherapy. A
total dose of at least 55Gy to the posterior fossa and
36Gy to the remaining cranial–spinal axis is needed; ad-
juvant chemotherapy might be useful in patients at high
risk of recurrence (Chang’s classification) especially if
distant metastases are present [3]. In adult patients, the
five-year progression-free survival rate ranges from 45%
to 75% depending on the risk class [2,3].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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toma has historically been poor, with most patients dying
of disseminated disease: usually within 12 to 15 months
after retreatment with either chemotherapy or radiother-
apy. The optimal treatment for local relapse in non-
metastatic patients remains controversial. A number of
chemotherapy regimens (with or without high-dose
chemotherapy and bone marrow autologous transplant-
ation) have been proposed, along with temozolomide
[4-6] and single-fraction stereotactic radio-surgery [7] or
stereotactic hypo-fractionated radiotherapy [8]. Re-
irradiation is frequently undertaken for isolated brain re-
lapses. A meta-analysis of brain re-irradiation found no
cases of necrosis if the total dose was lower than 100Gy
(two Gy/fraction; α:β = 2 Gy). A full dose re-irradiation
can be considered an option; it depends on the time
elapsed since primary treatment and on the feasibility of
a surgical resection of the recurrence [9].
Case presentation
The patient, a 31-year-old woman, complained of head-
ache and dizziness and underwent magnetic resonance
imaging (MRI) of the brain; this showed a contrast-
enhancing lesion in the posterior fossa. Radical removal
of the lesion was achieved by means of right posterior
fossa craniectomy and laminectomy of the first cervical
vertebra; histological examination confirmed the diagno-
sis of T2 (tumor greater than three cm and invading one
adjacent structure or partially filling fourth ventricle)
M0 (no gross subarachnoid or hematogenous metastasis)
(Chang’s classification), desmoplastic medulloblastoma.
At one month after surgery, cranio-spinal irradiation
was carried out. The entire cranio–spinal axis was
treated. The treatment consisted of two parallel opposed
photon fields, latero–lateral for the brain and posterior–
anterior for the spinal axis, using the moving junction
technique. The total dose to the brain and spinal axis
was 36Gy in 20 fractions (1.8Gy/fraction; five fractions/
week; one fraction/day). A boost to the posterior cranial
fossa (18Gy in 10 fractions) was then delivered, resulting
in a total dose to the tumor bed of 54Gy. Radiotherapy
was well tolerated and the patient did not show any
acute toxicity, with the exception of mild neutropenia
and nausea.
The patient underwent regular follow-up at the Radi-
ation Oncology Department without evidence of recur-
rent disease. Eight years later, MRI showed a recurrence
in the right cerebellum (cranio-caudal diameter, 5.7cm;
antero-posterior diameter, 4.7cm), causing a bulge in the
IV ventricle. Caudally the lesion imprinted the right cere-
bellar tonsil, resulting in a reduction in the ipsilateral for-
amen of Luschka. The patient was in good general
condition; neurological examination did not reveal any
neurological deficit. Neurocognitive analysis obtained bysubmitting the patient to a standardized neurological
examination using the Mini-MentalW State Examination
(MMSE), Clock Drawing Test, Rey auditory verbal learn-
ing test and Trail Making Test (TMT) indicated a normal
global cognitive function (MMSE, 28 out of 30), with im-
portant disexecutive and attention deficits (Clock Draw-
ing Test, three out of 10 and mild pathological TMT).
No memory impairment was detected using the MMSE
and Rey Auditory-Verbal Learning Tests.
After multidisciplinary clinical discussion the patient
underwent partial surgical resection of the recurrence.
The post-surgical MRI evidenced a small nodule on the
edge of the superior-medial cavity, showing post-
contrast enhancement that was suggestive of residual
disease. The patient then received salvage chemotherapy
including carboplatin, procarbazine, etoposide, cisplatin,
vincristine and cyclophosphamide according to the se-
quential trial of the French Society of Paediatric Oncol-
ogy [10]. After an initial response to treatment, the
patient refused high-dose chemotherapy with autologous
stem cell support. She continued with the same schedule
for about one year, until the disease progressed at the
margins of the surgical cavity, vermis and right cere-
bellar hemisphere. Second line palliative chemotherapy
with low-dose continuous temozolomide was adminis-
tered for three months without response. Brain, brain-
stem and spinal MRI showed a marked increase in the
number and size of the nodules present in the poster-
ior fossa (Figure 1 a,b). Given the occurrence of local
progression, the time that had elapsed from initial
radiotherapy (nine years) and the biological efficacy
dose (BED) of the first treatment (α:β = 2 Gy; 1.8Gy/
fraction in 30 fractions; BED = 102.6Gy), a salvage re-
irradiation was considered.
The patient signed an informed consent declaration,
after being informed of the possible acute and late toxic-
ities related to the re-irradiation. With the patient in the
supine treatment position and immobilized with a
thermoplastic mask, we obtained whole brain computed
tomography (CT) with three-mm slices from the vault of
the skull to C5. The volumes were defined on the plan-
ning CT and were co-registered and fused with the diag-
nostic MRI images (Figure 2 a,b). The planning target
volume consisted of the five-mm expansion of the clin-
ical target volume, encompassing the gross tumor vol-
ume and surgical cavity. Even if the total dose delivered
to the spinal liquoral spaces during the first line treat-
ment was lower than that to the posterior fossa, the
cord was not included in the treatment volume because
it was free of disease. The patient received three-
dimensional conformal radiotherapy to a total dose of
52.8Gy in 44 fractions over 22 days (1.2Gy/fraction; two
fractions daily; 10 fractions weekly; α:β = 2 Gy;
BED=122Gy).
Figure 1 a and b: The magnetic resonance imaging before re-irradiation. Recurrence of disease is clearly evident (arrows).
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and sub-acute toxicities were mild; slight somnolence
and asthenia disappeared within two months from
the end of the treatment. The patient continued with
follow-up at our institution. MRI, obtained at three
months after re-irradiation, showed complete regres-
sion of the multiple nodules in the posterior fossa
and no evidence of radionecrosis (Figure 3 a,b). Un-
fortunately, at 10 months after re-irradiation, the pa-
tient developed paraplegia. MRI revealed local relapse
and multiple sites of spinal recurrence of disease,
which were responsible for the reported symptoms
(Figure 4 a,b,c). Despite the fact that a radical re-
irradiation of the entire spine with a boost delivered
to macroscopic disease was considered, a palliative
treatment was chosen to treat only the sites of recur-
rence (30Gy in 10 fractions). At 18 months after re-Figure 2 a and b: Planning computed tomography with the retreatm
target volume identified in red (red arrow) and in blue (blue arrow), rirradiation, no radionecrosis or other late toxicities
were evident within the re-treated area on MRI.
Discussion
The risk of toxicity can differ between brain regions with
a highly collateralized blood supply and those perfused
by only a few small branches [11]. Importantly, and in
contrast to the spinal cord and other organs, few animal
studies regarding re-irradiation of the brain have been
published. Late injury is pathologically characterized by
demyelination, vascular changes and ultimately necrosis
[10]. Therefore, much attention has been paid to the ra-
diation response of the vasculature and the oligodendro-
cyte population. Radiation induces damage in endothelial
cells and the loss of 02A progenitor cells; this results in
failure to replace oligodendrocytes and subsequent de-
myelination [12]. However, the biology of late centralent gross tumor volume/clinical target volume and planning
espectively.
Figure 3 a and b: The magnetic resonance imaging performed at three months after re-irradiation showed complete remission (white arrows).
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namic process, possibly involving other cell types (astro-
cytes, microglia, neurons and neural stem cells) and
different cell interactions. No effective means of preven-
tion or treatment are known [10,12]. The response of
brain tissue to irradiation seems similar to that of the
spinal cord. Consequently, most of the available data are
extrapolated from studies on the spinal cord of rhesus
monkeys [13]. In humans, there is evidence that the risk
of myelopathy is low at radiation doses of up to a median
cumulative BED of 135Gy (α:β = 2 Gy for cervical and
thoracic cord and 4 Gy for lumbar cord), when the time
interval between re-irradiation is not shorter than six
months and the dose for each course is <98Gy BED [14].
Data exist concerning the re-irradiation of brain tumors
to a median cumulative BED2 (biological equivalent dose
in 2Gy fractions) of 200Gy, with at least one year be-
tween the two treatments; long-term complicationsFigure 4 a, b and c: The magnetic resonance imaging performed at o
spine and no brain toxicity (white arrows).related to the retreatment were seen in patients with a
BED2>204Gy (α:β = 2 Gy) [15].
In the largest published medulloblastoma re-irradiation
series (13 patients), the dose prescribed for the second
treatment was 30Gy (1.5Gy per fraction); the median
cumulative dose reached 82.3Gy (range 73.8 to 98.4Gy)
[10]. In this series, the treatment volumes included the
site of recurrence, and the spine was only re-irradiated if
it was the site of recurrence. Cranio-spinal irradiation
was carried out in just one of the cases because of the
time that had elapsed from the first treatment (eight
years).
The fractionation regimen (52.8Gy in 44 fractions;
1.2Gy/fraction; two fractions daily; 10 fractions weekly)
was chosen to take advantage of the early-repair charac-
teristics of medulloblastoma cells, as opposed to the late
repair of healthy brain tissue. The theoretical cumulative
BEDs for late and early effects on the healthy tissue ofne year after re-irradiation showed disease recurrence in the
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78Gy, respectively (Additional file 1). The initial treat-
ment involved a tumor BED of 102.6Gy, a late effects
BED of 86.4Gy and an early effects BED of 63.7Gy.
Therefore, the overall treatment involved a tumor BED
of 224.6Gy, a late reaction BED of 160.7Gy and an early
reaction BED of 141.7Gy, without taking into account
the recovery due to the gap between the first and the
second treatment. The total physical dose to the brain-
stem was limited to 49Gy.
Conclusions
In our experience, re-irradiation of recurrent medullo-
blastoma is feasible and safe without evidence of acute
or late toxicity after 18 months of follow-up. Even if
radionecrosis can occur later than 18 months, this
follow-up period can be considered a sufficient time
interval because a significant part of the slow repair
process occurs within one year. A radical dose (60Gy)
can be delivered, especially if given at low doses per frac-
tion. The spinal cord can possibly be included in the
treatment volume, even if it is not involved with the re-
currence, to avoid early spinal progression.
Because of concerns with regard to the risk of late
central nervous system toxicity, especially radionecrosis
that may occur several months to years after treatment,
radiation oncologists have historically been cautious
about retreating brain tumors. However, there is a lack
of prospective data in this regard. Re-irradiation of brain
tumors is attracting increasing interest. In fact, a greater
understanding of brain tolerance to radiation, develop-
ments in tumor imaging and advances in radiotherapy
planning and delivery techniques now make possible the
achievement of better target definition and highly con-
formal treatments.
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